<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01404936</url>
  </required_header>
  <id_info>
    <org_study_id>DM96-060</org_study_id>
    <nct_id>NCT01404936</nct_id>
  </id_info>
  <brief_title>Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) With Hodgkin's Disease</brief_title>
  <official_title>A Phase II Study of a-Interferon With Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD) for Patients With Hodgkin's Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Schering-Plough</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a clinical research study of interferon (IFN) plus chemotherapy with the standard
      combination of Adriamycin, Bleomycin, Velban, and Dacarbazine (ABVD). The treatment will be
      given to patients with Hodgkin's disease. The study will look at whether adding IFN to ABVD
      improves the immune response against Hodgkin's disease, and will determine whether the
      toxicity of ABVD is increased by adding IFN.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Each treatment cycle will last 2 weeks. On days 1 - 4 of each cycle, patients will be given a
      shot of IFN under the skin. On day 4, patients will be given ABVD through a vein over
      one-hour.

      The plan is for patients to receive 12 cycles of treatment. However, patients will leave the
      study if they have severe side effects or if the cancer grows or spreads. They will also
      leave if the cancer does not improve after 6 cycles. Patient who leave the study will be
      offered other treatments. A maximum of 35 patients will be treated with that dose.

      Before the first treatment, patient will have a physical exam, blood tests, and a heart scan.
      Within 1 month of starting treatment, patients will have a chest X-ray, CT scans of the
      abdomen and pelvis, and a gallium scan.

      During the study, patient will have blood tests every week and a physical exam every 2 weeks.
      The X-ray, CT scans, and gallium scan will be repeated after cycles 6 and 12.

      All the drugs in this study are approved by the U.S. Food and Drug Administration and are
      available by prescription. ABVD is a standard treatment for Hodgkin's disease; IFN is an
      investigational treatment for Hodgkin's disease. About 35 patients will be enrolled in the
      study. All treatment will be given in the outpatient clinic at M.D. Anderson Cancer Center.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 1996</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Participants' Response</measure>
    <time_frame>After 6 courses (3 months)</time_frame>
    <description>Complete Response (CR): Disappearance of all clinical evidence of active tumors for a minimum of 8 weeks. Partial Response (PR): 50% or greater decrease in sum of products all measured lesions persisting for at least 4 weeks. No Change: Steady state or change of +/- 25% of tumor size and no progression for minimum of 8 weeks with no appearance of new lesions. Progressive Disease: &gt; 25 % increase in size of any measurable lesion or appearance of significant new lesions.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">35</enrollment>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Interferon-2A + Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon-2A</intervention_name>
    <description>4 (x106 IU/m^2) subcutaneously on days 1-4.</description>
    <arm_group_label>Interferon-2A + Chemotherapy</arm_group_label>
    <other_name>Interferon-Alfa-2a</other_name>
    <other_name>Roferon-A</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adriamycin</intervention_name>
    <description>25 mg/m^2 by vein on day 4.</description>
    <arm_group_label>Interferon-2A + Chemotherapy</arm_group_label>
    <other_name>Doxorubicin</other_name>
    <other_name>Rubex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bleomycin</intervention_name>
    <description>10 mg/m^2 by vein on day 4.</description>
    <arm_group_label>Interferon-2A + Chemotherapy</arm_group_label>
    <other_name>Bleomycin Sulfate</other_name>
    <other_name>BLM</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Velban</intervention_name>
    <description>6 mg/m^2 by vein on day 4.</description>
    <arm_group_label>Interferon-2A + Chemotherapy</arm_group_label>
    <other_name>Vinblastine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dacarbazine</intervention_name>
    <description>375 mg/m^2 by vein on day 4.</description>
    <arm_group_label>Interferon-2A + Chemotherapy</arm_group_label>
    <other_name>DTIC-DOME</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Hodgkin's disease patients who relapse after radiation therapy alone, or in
             combination with Novantrone, Oncovin, Velban, and Prednisone (NOVP); and previously
             untreated patients with stage III and IV who are eligible for standard ABVD therapy.

          2. Must have adequate bone marrow reserve Absolute neutrophil count (ANC) &gt; 1,000/uL,
             Platelets &gt; 100,000

          3. Left ventricular ejection fraction (LVEF) &gt;/= 50%, serum creatinine &lt; 2mg/dl, serum
             bilirubin &lt; 2mg/dl

        Exclusion Criteria:

          1. No prior therapy with Mustargen Oncovin Procarbazine Prednisone (MOPP).

          2. No severe pulmonary disease including Chronic obstructive pulmonary disease (COPD) and
             asthma.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anas Younes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT MD Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UT MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mdanderson.org</url>
    <description>UT MD Anderson Website</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 26, 2011</study_first_submitted>
  <study_first_submitted_qc>July 27, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2011</study_first_posted>
  <results_first_submitted>December 21, 2012</results_first_submitted>
  <results_first_submitted_qc>January 30, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 1, 2013</results_first_posted>
  <last_update_submitted>January 30, 2013</last_update_submitted>
  <last_update_submitted_qc>January 30, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 1, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Lymphoma</keyword>
  <keyword>Hodgkin's Disease</keyword>
  <keyword>Stage III and IV</keyword>
  <keyword>Adriamycin</keyword>
  <keyword>Doxorubicin</keyword>
  <keyword>Rubex</keyword>
  <keyword>Bleomycin</keyword>
  <keyword>Bleomycin Sulfate</keyword>
  <keyword>BLM</keyword>
  <keyword>Dacarbazine</keyword>
  <keyword>DTIC-DOME</keyword>
  <keyword>Interferon-2A</keyword>
  <keyword>Interferon-Alfa-2a</keyword>
  <keyword>Roferon-A</keyword>
  <keyword>Velban</keyword>
  <keyword>Vinblastine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hodgkin Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
    <mesh_term>Bleomycin</mesh_term>
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Vinblastine</mesh_term>
    <mesh_term>Dacarbazine</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment Period: July 25, 1996 through March 3, 2000. All participants were recruited at UT MD Anderson Cancer Center.</recruitment_details>
      <pre_assignment_details>Of the 35 participants registered, five (5) were excluded from the trial.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Interferon-2A + Chemotherapy</title>
          <description>Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Interferon-2A + Chemotherapy</title>
          <description>Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30" lower_limit="18" upper_limit="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Participants' Response</title>
        <description>Complete Response (CR): Disappearance of all clinical evidence of active tumors for a minimum of 8 weeks. Partial Response (PR): 50% or greater decrease in sum of products all measured lesions persisting for at least 4 weeks. No Change: Steady state or change of +/- 25% of tumor size and no progression for minimum of 8 weeks with no appearance of new lesions. Progressive Disease: &gt; 25 % increase in size of any measurable lesion or appearance of significant new lesions.</description>
        <time_frame>After 6 courses (3 months)</time_frame>
        <population>Two patients did not complete therapy; however, they were included in the intent-to-treat analysis. One patient was censored at the last follow-up date since no events had occurred.</population>
        <group_list>
          <group group_id="O1">
            <title>Interferon-2A + Chemotherapy</title>
            <description>Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)</description>
          </group>
        </group_list>
        <measure>
          <title>Participants' Response</title>
          <description>Complete Response (CR): Disappearance of all clinical evidence of active tumors for a minimum of 8 weeks. Partial Response (PR): 50% or greater decrease in sum of products all measured lesions persisting for at least 4 weeks. No Change: Steady state or change of +/- 25% of tumor size and no progression for minimum of 8 weeks with no appearance of new lesions. Progressive Disease: &gt; 25 % increase in size of any measurable lesion or appearance of significant new lesions.</description>
          <population>Two patients did not complete therapy; however, they were included in the intent-to-treat analysis. One patient was censored at the last follow-up date since no events had occurred.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="30"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uncomfirmed Complete Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Partial Response</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progressive Disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>3 years and 4 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Interferon-2A + Chemotherapy</title>
          <description>Interferon-2A 4 (x106 IU/m^2) subcutaneously Day 1 - 4 + ABVD Chemotherapy on Day 4 (ABVD: Adriamycin 25 mg/m2 intravenous (IV), Bleomycin 10 mg/m^2 IV, Velban 6 mg/m2 IV, and Dacarbazine 375 mg/m2 IV)</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Psychiatric Disorders</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="30"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Anas Younes, MD / Professor</name_or_title>
      <organization>UT MD Anderson Cancer Center</organization>
      <email>CR_Study_Registration@mdanderson.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

